Prodrug-inspired probes selective to cathepsin B over other cysteine cathepsins.
暂无分享,去创建一个
Ingeborg Zehbe | I. Zehbe | Cody C McMillan | Morshed A Chowdhury | Ignace A Moya | Shardul Bhilocha | Brady G Vigliarolo | Christopher P Phenix | M. Chowdhury | C. P. Phenix | Shardul Bhilocha | I. Moya
[1] J. Joyce,et al. Proteolytic networks in cancer. , 2011, Trends in cell biology.
[2] A. Barrett,et al. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. , 1982, The Biochemical journal.
[3] C. D. Arnett,et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. , 1987, Science.
[4] Olga Vasiljeva,et al. Cysteine cathepsins: From structure, function and regulation to new frontiers☆ , 2011, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics.
[5] A. D'Amico,et al. An image contrast agent selectively activated by prostate specific antigen. , 2006, Bioorganic & medicinal chemistry.
[6] P. Trail,et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.
[7] G. Dubowchik,et al. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. , 1998, Bioorganic & medicinal chemistry letters.
[8] B. Rzeszotarska,et al. A Large Scale Synthesis of Mono- and Di-urethane Derivatives of Lysine , 1999 .
[9] R. Weissleder,et al. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.
[10] F. Kratz,et al. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs. , 2009, Bioconjugate chemistry.
[11] J. Barrio,et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. , 2005, Gastroenterology.
[12] Francesco Leonetti,et al. Substrate Profiling of Cysteine Proteases Using a Combinatorial Peptide Library Identifies Functionally Unique Specificities* , 2006, Journal of Biological Chemistry.
[13] G. Salvesen,et al. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. , 2002, Current pharmaceutical design.
[14] Andrew E. Sloan,et al. Topical Application of Activity-based Probes for Visualization of Brain Tumor Tissue , 2012, PloS one.
[15] R. Jain,et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.
[16] Daniel E Koshland. The application and usefulness of the ratio k(cat)/K(M). , 2002, Bioorganic chemistry.
[17] J. Katzenellenbogen,et al. A novel connector linkage applicable in prodrug design. , 1981, Journal of medicinal chemistry.
[18] D. Hicklin,et al. Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts , 2006, Clinical Cancer Research.
[19] C. Olsen,et al. Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme. , 2012, Journal of medicinal chemistry.
[20] E. Brogi,et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.
[21] I. Shin,et al. Dual-targeting delivery system for selective cancer cell death and imaging , 2013 .
[22] J. Kos,et al. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. , 2003, Experimental cell research.
[23] V. Turk,et al. Cysteine cathepsins are not critical for TRAIL- and CD95-induced apoptosis in several human cancer cell lines , 2012, Biological chemistry.
[24] Bonnie F. Sloane,et al. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion , 2011, Breast Cancer Research.
[25] Raphael Dumeunier,et al. Latent fluorophores based on a self-immolative linker strategy and suitable for protease sensing. , 2008, Bioconjugate chemistry.
[26] Georges von Degenfeld,et al. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. , 2007, Nature chemical biology.
[27] R. Bjerkvig,et al. The regulation of cysteine cathepsins and cystatins in human gliomas , 2012, International journal of cancer.
[28] D. Turk,et al. Revised Definition of Substrate Binding Sites of Papain-Like Cysteine Proteases , 1998, Biological chemistry.
[29] M. Bogyo,et al. Non-Invasive Imaging of Cysteine Cathepsin Activity in Solid Tumors Using a 64Cu-Labeled Activity-Based Probe , 2011, PloS one.
[30] Bonnie F. Sloane,et al. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. , 1994, The American journal of pathology.
[31] Kwangmeyung Kim,et al. Cathepsin B-sensitive nanoprobe for in vivo tumor diagnosis , 2011 .
[32] Damon L. Meyer,et al. Contribution of linker stability to the activities of anticancer immunoconjugates. , 2008, Bioconjugate chemistry.
[33] Bonnie F. Sloane,et al. Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. , 2005, Seminars in cancer biology.
[34] Bonnie F. Sloane,et al. Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.
[35] Shuji Ogino,et al. Cathepsin B Expression and Survival in Colon Cancer: Implications for Molecular Detection of Neoplasia , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[36] Chun-Wei Peng,et al. Cathepsin B cleavable novel prodrug Ac‐Phe‐Lys‐PABC‐ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis , 2012, Cancer.
[37] K. Jaskiewicz,et al. Overexpression of cathepsin B correlates with angiogenesis in colon adenocarcinoma. , 2004, Neoplasma.
[38] G. Taraboletti,et al. Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. , 2008, Neoplasia.
[39] H. Hausen,et al. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. , 1984, The EMBO journal.
[40] W. Bode,et al. HUMAN CATHEPSIN G , 1997 .
[41] G. Lalmanach,et al. CA-074, But Not Its Methyl Ester CA-074Me, Is a Selective Inhibitor of Cathepsin B within Living Cells , 2002, Biological chemistry.
[42] T. Lah,et al. Post-Translational Regulation of Cathepsin B, but not of Other Cysteine Cathepsins, Contributes to Increased Glioblastoma Cell Invasiveness In Vitro , 2009, Pathology & Oncology Research.
[43] H. Chapman,et al. Human Cathepsin F , 1998, The Journal of Biological Chemistry.
[44] Matthew Bogyo,et al. Activity-based probes that target diverse cysteine protease families , 2005, Nature chemical biology.
[45] Bonnie F. Sloane,et al. Cathepsin B: a potential prognostic marker for inflammatory breast cancer , 2011, Journal of Translational Medicine.
[46] C. P. Huber,et al. Characterization of cathepsin B specificity by site-directed mutagenesis. Importance of Glu245 in the S2-P2 specificity for arginine and its role in transition state stabilization. , 1993, The Journal of biological chemistry.